Clinical Proteomics Center in Lung Disease

描述（由申请人提供）： 肺部疾病是所有年龄段发病率和死亡率的重要原因。迫切需要开发和验证生物标志物，以帮助诊断和管理肺部疾病患者。特别是，可以非侵入性地获得的蛋白质生物标志物的组合提供了很大的希望。我们建议建立一个多学科的肺部疾病临床蛋白质组学中心，以快速开发和验证可用于诊断，疾病诊断和治疗儿科和成人肺部疾病的蛋白质生物标志物。 我们将基于我们的计划大，充分表征儿科和成人患者群体，并在生物标志物研究的广泛专业知识。临床蛋白质组学计划将包括生物标志物开发的分阶段模型，包括通过回顾性和前瞻性临床验证进行分析验证，以实现大规模应用。分阶段开发策略有几个优点，包括仔细、快速地评估新型生物标志物;将小组规模减少到临床上有用的最低限度;以及最大限度地利用以前现有的国家疾病网络。我们的具体目标是：1.建立一个具有五个核心（临床，实验室，数据管理/生物统计，教育和行政）的中心，以选择，验证，应用和不断改进蛋白质生物标志物面板。2.开发特异性蛋白质生物标志物面板，旨在预测疾病进展，评估加重的可能性和意义，并评估慢性阻塞性肺疾病，哮喘，急性肺损伤，婴儿慢性肺疾病，肺动脉高压和囊性纤维化的治疗反应。3.为医学博士，博士，医学博士/博士，实验室人员和研究协调员创建一个地方和国家的教育和技能发展计划，在临床蛋白质组学和4。为对开发肺部疾病蛋白质生物标志物感兴趣的研究人员建立国家资源。

DESCRIPTION (provided by applicant): Lung disease is an important cause of morbidity and mortality at all ages. There is a pressing need for development and validation of biomarkers to aid in the diagnosis and management of patients with lung disease. In particular, combinations of protein biomarkers that can be obtained non-invasively offer great promise. We propose to establish a multidisciplinary Clinical Proteomics Center in Lung Disease to rapidly develop and validate panels of protein biomarkers that can be used in diagnosis, disease prognostication, and treatment of pediatric and adult lung disorders. We will base our program on large, well-characterized pediatric and adult patient populations, and extensive expertise in biomarker research. The Clinical Proteomics Program will consist of a phased model of biomarker development encompassing assay validation through retrospective and prospective clinical validation to large scale application. The phased development strategy has several advantages including careful, expeditious evaluation of novel biomarkers; reduction in panel size to the minimum that is clinically useful; and maximum utilization of previously existing national disease networks. Our specific aims will be to: 1. Establish a center with five cores (Clinical, Laboratory, Data Management/Biostatistics, Educational, and Administrative) to select, validate, apply and continually improve protein biomarker panels. 2. Develop specific protein biomarker panels aimed at predicting progression of disease, assessing likelihood and significance of exacerbation, and evaluating response to treatment in Chronic Obstructive Pulmonary Disease, Asthma, Acute Lung Injury, Chronic Lung Disease of Infancy, Pulmonary Arterial Hypertension and Cystic Fibrosis. 3. Create a local and national educational and skills development program for MDs, PhDs, MD/PhDs, Laboratory Personnel and Research Coordinators, in Clinical Proteomics and 4. Establish a national resource for investigators interested in developing protein biomarkers of lung disease.